Congress digests
Each congress, distilled to the findings that changed something in this map, with a source for every item and links to the technologies, products, and trials it touches.
Triple-negative breast cancer moved to an ADC-first world, the largest cancer screening trial ever run reported mixed results, and immunotherapy kept extending its reach in the curative setting.
Oral SERDs and PROTACs consolidated their place in ESR1-mutant disease, T-DXd de-escalation strategies matured in HER2+ early breast cancer, and the limits of giving one ADC straight after another became clearer.
The next ADC generation showed its shape: bispecific and dual-payload constructs, new targets (MERTK, CDCP1, LRRC15, STn, integrin αvβ6, ALPP), and AI-nominated antigens, almost all carrying topoisomerase-I payloads.
Alpha-emitting PSMA therapy produced its cleanest first-in-human data yet, and PSMA PET continued to reshape staging and treatment selection.